Advisor Group Holdings, Inc. Leap Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.29 - $0.72 $571 - $1,418	1,970 Added 1.08%	183,895 $62,000
Q4 2022 Feb 10, 2023	BUY	$0.42 - $9.18 $33,180 - $725,220	79,000 Added 76.75%	181,925 $81,000
Q3 2022 Nov 14, 2022	BUY	$0.92 - $9.3 $26,220 - $265,050	28,500 Added 38.29%	102,925 $90,000
Q2 2022 Aug 10, 2022	BUY	$0.96 - $1.91 $22,560 - $44,885	23,500 Added 46.15%	74,425 $85,000
Q1 2022 May 04, 2022	BUY	$1.6 - $3.35 $13,320 - $27,888	8,325 Added 19.54%	50,925 $89,000
Q2 2021 Aug 02, 2021	SELL	$1.48 - $1.92 $14,800 - $19,200	-10,000 Reduced 19.01%	42,600 $70,000
Q3 2020 Nov 12, 2020	BUY	$1.68 - $2.17 $88,368 - $114,142	52,600 New	52,600 $104,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $275M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.